Quantifying the risk of SARS‐CoV‐2 reinfection over time. (27th May 2021)

• Record Type: Journal Article
• Authors: O Murchu, Eamon; Byrne, Paula; Carty, Paul G.; De Gascun, Cillian; Keogan, Mary; O'Neill, Michelle; Harrington, Patricia; Ryan, Máirín
• Is Part Of: Reviews in medical virology. Volume 32:Number 1(2022)
• Page Start: n/a
• Page End: n/a
• Publication Date: 2021-05-27
• Subjects: COVID‐19 -- SARS‐CoV‐2 -- reinfection; Medical virology -- Periodicals; Review Literature -- Periodicals; Virus Diseases -- Periodicals; Viruses -- Periodicals; 616.0194
• DOI: 10.1002/rmv.2260
• Languages: English
• ISSNs: 1052-9276

Abstract

Summary: Despite over 140 million SARS‐CoV‐2 infections worldwide since the beginning of the pandemic, relatively few confirmed cases of SARS‐CoV‐2 reinfection have been reported. While immunity from SARS‐CoV‐2 infection is probable, at least in the short term, few studies have quantified the reinfection risk. To our knowledge, this is the first systematic review to synthesise the evidence on the risk of SARS‐CoV‐2 reinfection over time. A standardised protocol was employed, based on Cochrane methodology. Electronic databases and preprint servers were searched from 1 January 2020 to 19 February 2021. Eleven large cohort studies were identified that estimated the risk of SARS‐CoV‐2 reinfection over time, including three that enrolled healthcare workers and two that enrolled residents and staff of elderly care homes. Across studies, the total number of PCR‐positive or antibody‐positive participants at baseline was 615, 777, and the maximum duration of follow‐up was more than 10 months in three studies. Reinfection was an uncommon event (absolute rate 0%–1.1%), with no study reporting an increase in the risk of reinfection over time. Only one study estimated the population‐level risk of reinfection based on whole genome sequencing in a subset of patients; the estimated risk was low (0.1% [95% CI: 0.08–0.11%]) with no evidence of waning immunity for up to 7 months following primary infection. These data suggest that naturally acquired SARS‐CoV‐2 immunity does not wane for at least 10 months post‐infection. However, the applicability of these studies to new variants or to vaccine‐induced immunity remains uncertain.